XRAY

$12.22

Post-MarketAs of Mar 17, 8:00 PM UTC

DENTSPLY SIRONA Inc.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Motley Fool
Mar 13, 2026

Is Dentsply Sirona Stock a Buy After a Company Director Purchased 15,000 Shares?

This global dental technology firm, with strong recurring revenues, reported a notable insider buy following a year of share price declines.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 12, 2026

3 Cash-Producing Stocks Walking a Fine Line

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 9, 2026

3 Stocks Under $50 Walking a Fine Line

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 8, 2026

How The Dentsply Sirona (XRAY) Story Is Shifting As Analysts Rework Valuation And Risks

The updated model lifts DENTSPLY SIRONA’s fair value estimate from US$12.97 to US$14.43, putting fresh focus on how the stock’s upside case is being recalibrated. This shift lines up with recent Street work, where several firms have moved price targets higher while keeping a mixed stance on how much execution risk remains. As you read on, you will see how these target changes fit into the evolving narrative and what to watch if you are tracking this story over time. Analyst Price Targets...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 8, 2026

A Look At Dentsply Sirona (XRAY) Valuation After Mixed Earnings And Impairment Charges

DENTSPLY SIRONA (XRAY) has been back in focus after its latest quarterly update combined revenue that beat expectations with an adjusted earnings per share miss, softer full year guidance, and fresh impairment charges, keeping sentiment cautious. See our latest analysis for DENTSPLY SIRONA. Recent earnings, new 2026 sales guidance and sizeable non cash impairments have come against a backdrop of a 13.2% 7 day share price decline and an 18.1% 1 year total shareholder return loss, despite a...

BEARISH
Negative press. News cycle fixated on risk factors or misses.